Ameriprise
ATOS icon

Ameriprise’s Atossa Therapeutics ATOS Stock Holding History

Ameriprise’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
255,134
+2,397
+0.9% +$15.2K ﹤0.01% 3158
2025
Q4 		$2.24M Buy
252,737
+55,970
+28% +$708K ﹤0.01% 2933
2025
Q3 		$2.56M Sell
196,767
-1,447
-0.7% -$17.9K ﹤0.01% 2882
2025
Q2 		$2.47M Buy
+198,214
New +$2.37M ﹤0.01% 2829
2022
Q4 		– Sell
-734
Closed -$9K – 3961
2022
Q3 		$9K Sell
734
-8
-1% -$116 ﹤0.01% 3937
2022
Q2 		$12K Sell
742
-218
-23% -$3.44K ﹤0.01% 3861
2022
Q1 		$18K Buy
+960
New +$19.5K ﹤0.01% 3905
2021
Q4 		– Sell
-1,990
Closed -$97K – 3959
2021
Q3 		$97K Buy
1,990
+1,098
+123% +$63.9K ﹤0.01% 3780
2021
Q2 		$85K Buy
+892
New +$47.2K ﹤0.01% 3834

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return